Suitcase in my hand

Discovering further similarities

We discovered further similarities between the Kansas City Court Report and our dealings with Tamiflu.

The legal report underscored a crucial point: "In its press release announcing emergency use authorisation for its COVID-19 vaccine, Pfizer did not disclose that it had excluded immunocompromised individuals from its COVID-19 vaccine trials.”

Instead, in “Important Safety Information” in its press release, Pfizer noted that

“[i]mmunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer BioNTech COVID-19 Vaccine.”

The 2001 Weliver trial, published in JAMA,  investigated the efficacy of oseltamivir in preventing the spread of influenza to household contacts of influenza-infected index cases. Only when we had access to the CSR  (WV15799) could we assess the full extent of the exclusions. 

A second point in the Kansas legal report was that  Pfizer only tested the booster shot on twelve 65-to-85-year-old trial partic…